

13. (Reiterated) The method of claim 1, wherein the disorder is characterized by pre-cancerous, cancerous or neoplastic cells, or the presence of a tumour.

14. (Reiterated) The method of claim 13, wherein the disorder affects an epithelial tissue.

15. (Reiterated) The method of claim 1, wherein the disorder is characterized by unwanted skin cell proliferation.

16. (Reiterated) The method of claim 15, wherein the disorder is a squamous cell carcinoma of the skin or a malignant melanoma.

17. (Reiterated) The method of claim 1, wherein the disorder is characterized by unwanted prostate cell proliferation.

Cp Sub 12/ 18. (Amended) The method of claim 1, wherein the disorder is characterized by benign unwanted skin proliferation.

---

19. (Reiterated) The method of claim 18, wherein the disorder is psoriasis or papilloma formation.

20. (Reiterated) The method of claim 1, further comprising increasing TSP-1 activity.

21. (Reiterated) The method of claim 1 or claim 20, further comprising inhibiting VEGF activity.

22. (Reiterated) The method of claim 1, further comprising administering a chemotherapeutic agent.

23. (Reiterated) The method of claim 22, wherein the chemotherapeutic agent is taxol or carboplatin.

53. (Reiterated) The method of claim 1, wherein the fragment is up to 100 amino acids in length.

54. (Reiterated) The method of claim 53, wherein the fragment is up to 50 amino acids in length.

55. (Reiterated) The method of claim 1, wherein the fragment is at least 50 amino acids in length.

56. (Reiterated) The method of claim 1, wherein the fragment is at least 100 amino acids in length.

57. (Reiterated) The method of claim 1, wherein the fragment is at least 200 amino acids in length.

58. (Amended) The method of claim 1, wherein the fragment comprises at least one type I repeat.

59. (Reiterated) The method of claim 1, wherein the fragment includes between about 5 to 50 amino acids of a type I repeat.

C7 Sub D2 60. (Amended) The method of claim 1, wherein the fragment comprises at least one sequence selected from the group of: amino acids 382-429 of SEQ ID NO:2, amino acids 438-490 of SEQ ID NO:2, and amino acids 495-547 of SEQ ID NO:2.

61. (Reiterated) The method of claim 1, wherein the fragment comprises SEQ ID NO:11.

63. (Amended) The method of claim 1, wherein the fragment comprises a procollagen domain or a fragment thereof having the ability to inhibit endothelial cell migration.

*Sub D21*  
*C8* 64. (Amended) The method of claim 1, wherein the fragment comprises SEQ ID NO:6.

65. (Amended) The method of claim 1, wherein the fragment comprises SEQ ID NO:7.

66. (Amended) The method of claim 1, wherein the fragment comprises SEQ ID NO:8.

67. (Amended) The method of claim 1, wherein the fragment comprises SEQ ID NO:9.

68. (Reiterated) The method of claim 1, wherein the fragment comprises a fragment of SEQ ID NO:10 at least 4 amino acids in length.

Add new claims 75-87, as follows.

75. The method of claim 1, wherein the fragment comprises two type I repeats.

*Sub D21*  
*C9* 76. The method of claim 1, wherein the fragment comprises three type I repeats.

77. The method of claim 1, wherein the fragment comprises an amino acid sequence encoded by nucleotides 294-1367 of SEQ ID NO:1.

78. The method of claim 1, wherein the fragment comprises an amino acid sequence encoded by nucleotides 294-1883 of SEQ ID NO:1.

79. The method of claim 1, wherein the fragment comprises an amino acid sequence encoded by nucleotides 1383-1883 of SEQ ID NO:1.

80. The method of claim 1, wherein the disorder is colon cancer.

81. The method of claim 1, wherein the disorder is breast cancer.

82. The method of claim 1, wherein the disorder is lung cancer.

83. The method of claim 1, wherein the disorder is Kaposi's sarcoma.

84. The method of claim 1, wherein the TSP-2 has an amino acid sequence at least 95% identical to the sequence of SEQ ID NO:2.

85. The method of claim 1, wherein the TSP-2 has an amino acid sequence at least 98% identical to the sequence of SEQ ID NO:2.

86. The method of claim 1, wherein the TSP-2 has an amino acid sequence at least 99% identical to the sequence of SEQ ID NO:2.

87. A method of treating a subject having a disorder characterized by unwanted cell proliferation, the method comprising:

identifying a subject having a disorder characterized by unwanted cell proliferation; and  
administering to the subject a polypeptide comprising the amino acid sequence of  
SEQ ID NO:2 (TSP-2) or a fragment thereof capable of inhibiting endothelial cell migration.

In the drawings:

Please substitute the enclosed 7 sheets of formal drawings for the corresponding drawings presently in the application.